Alembic Pharma surges on getting USFDA’s final approval for Travoprost Ophthalmic Solution

24 Dec 2019 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 547.00, up by 6.65 points or 1.23% from its previous closing of Rs. 540.35 on the BSE.

The scrip opened at Rs. 540.00 and has touched a high and low of Rs. 546.60 and Rs. 538.00 respectively. So far 812 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 612.75 on 18-Jan-2019 and a 52 week low of Rs. 435.10 on 21-Jun-2019.

Last one week high and low of the scrip stood at Rs. 562.60 and Rs. 538.00 respectively. The current market cap of the company is Rs. 10300.51 crore.

The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 15.97% and 11.06% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost Ophthalmic Solution USP, 0.004%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Travatan Ophthalmic Solution, 0.004%, of Alcon Pharmaceuticals Limited (Alcon). Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Alembic has a cumulative total of 110 ANDA approvals (97 final approvals and 13 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

964.50 11.90 (1.25%)
14-May-2024 10:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.25
Dr. Reddys Lab 5873.00
Cipla 1383.95
Zydus Lifesciences 1000.90
Lupin 1653.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.